Stroke patients with normal, but not those with impaired, renal function have greater benefit with ticagrelor-aspirin than clopidogrel-aspirin<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Nov. 1, 2022 (HealthDay News) — Among CYP2C19<\/em> loss-of-function allele carriers with minor stroke or transient ischemic attack, those with normal renal function rather than impaired renal function derive greater benefit from ticagrelor-aspirin versus clopidogrel-aspirin, according to research published online Nov. 1 in the Annals of Internal Medicine<\/em>.<\/p>\n Anxin Wang, Ph.D., from Beijing Tiantan Hospital and Capital Medical University, and colleagues examined the effect of renal function on the efficacy and safety of ticagrelor-aspirin versus clopidogrel-aspirin treatment in a post hoc analysis of a randomized trial conducted at 202 centers in China. Data were included for 6,378 patients: 63.5, 31.5, and 5.0 percent had normal, mildly decreased, and moderately to severely decreased renal function (estimated glomerular filtration rates, \u00e2\u0089\u00a590, 60 to 89, and <60 mL\/min\/1.73 m2<\/sup>, respectively).<\/p>\n The researchers found that for normal, mildly decreased, and moderately to severely decreased renal function, the differences in recurrent stroke between ticagrelor-aspirin and clopidogrel-aspirin were \u00e2\u0088\u00922.8 percent (hazard ratio, 0.63; 95 percent confidence interval, 0.49 to 0.81), \u00e2\u0088\u00920.2 percent (hazard ratio, 0.98; 95 percent confidence interval, 0.69 to 1.39), and 3.7 percent (hazard ratio, 1.31; 95 percent confidence interval, 0.48 to 3.55). There was no substantial difference seen in the rates of severe or moderate bleeding by treatment assignments across estimated glomerular filtration rate categories.<\/p>\n “The findings suggest that renal function should be considered when deciding on the use of ticagrelor-aspirin versus clopidogrel-aspirin,” the authors write.<\/p>\n Salubris Pharmaceuticals contributed ticagrelor, clopidogrel, and placebo for the study at no cost and with no restrictions.<\/p>\n <\/span>Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n